Crestor and Diphenhydramine Interaction: What the Evidence Actually Shows

Why This Combination Raises Questions

Patients prescribed rosuvastatin for hyperlipidemia or atherosclerotic cardiovascular disease (ASCVD) prevention frequently reach for over-the-counter diphenhydramine to manage allergies, insomnia, or cold symptoms. The question is reasonable. Statins carry a well-known interaction profile with drugs that share hepatic metabolism or transport pathways, and diphenhydramine inhibits cytochrome P450 2D6 (CYP2D6) at therapeutic concentrations [1]. A 2020 review in Clinical Pharmacology & Therapeutics confirmed that CYP2D6 inhibition by first-generation antihistamines is clinically measurable at standard 25-50 mg doses [2].

The concern, though, collapses once you examine the specific metabolic routes of rosuvastatin. Unlike atorvastatin or simvastatin, which depend heavily on CYP3A4, rosuvastatin undergoes minimal phase I metabolism. The FDA-approved prescribing information for Crestor states that approximately 90% of the absorbed dose is eliminated unchanged, with CYP2C9 responsible for a limited portion of its biotransformation and CYP2C19 playing an even smaller role [3]. CYP2D6 is not involved.

Pharmacokinetic Analysis: CYP Enzymes and Transporter Proteins

Rosuvastatin's hepatic uptake relies on organic anion transporting polypeptides OATP1B1 and OATP1B3, along with breast cancer resistance protein (BCRP) for efflux [3]. Drugs that inhibit these transporters (cyclosporine, certain protease inhibitors, gemfibrozil) can raise rosuvastatin plasma concentrations two- to seven-fold, producing genuine safety signals [4]. That is the interaction pathway that matters for this statin.

Diphenhydramine does not appear in any published list of OATP1B1/1B3 inhibitors. A 2018 Drug Metabolism and Disposition study screening 294 marketed drugs for OATP1B1 inhibition at clinically relevant concentrations did not flag diphenhydramine as a significant inhibitor [5]. The drug's primary metabolic fate runs through CYP2D6, with secondary contributions from CYP1A2, CYP2C9, and CYP2C19, followed by renal excretion of demethylated and deaminated metabolites [6].

Where the two drugs' metabolic maps do technically overlap is CYP2C9. Rosuvastatin is a minor CYP2C9 substrate, and diphenhydramine has weak inhibitory activity at this enzyme. But the magnitude is too small to matter. Because CYP2C9 handles only about 10% of rosuvastatin clearance, even moderate CYP2C9 inhibition would produce a negligible change in area under the curve (AUC) [3]. Compare this to the cyclosporine-rosuvastatin interaction, where OATP1B1 blockade increases rosuvastatin AUC by 7.1-fold and Cmax by 10.6-fold, requiring a hard dose cap of 5 mg daily [4].

No published pharmacokinetic study has measured the effect of diphenhydramine co-administration on rosuvastatin plasma levels directly. The absence of data here is itself informative. Regulatory agencies and DDI database curators (Lexicomp, Clinical Pharmacology, Micromedex) classify this pair as having no expected clinically significant pharmacokinetic interaction [7].

Pharmacodynamic Considerations

The pharmacodynamic side of this combination deserves a brief assessment even though the pharmacokinetic interaction is absent. Rosuvastatin's FDA label lists dizziness, headache, and insomnia among less common adverse effects [3]. Diphenhydramine, as a potent H1-inverse agonist and muscarinic antagonist, causes dose-dependent sedation, cognitive impairment, and anticholinergic effects including dry mouth, urinary retention, and constipation [6].

These pharmacodynamic profiles do not overlap in a way that amplifies toxicity. Statin-associated muscle symptoms (SAMS), the most clinically relevant adverse effect of rosuvastatin, are not worsened by antihistamines. The 2014 National Lipid Association (NLA) Statin Muscle Safety Task Force statement identified specific risk factors for SAMS: advanced age, hypothyroidism, renal impairment, high-dose statin therapy, and co-administration of CYP3A4 inhibitors (for CYP3A4-metabolized statins) [8]. Antihistamines were not listed.

One scenario where pharmacodynamic caution is warranted involves older adults already carrying a high anticholinergic burden. The 2023 update to the American Geriatrics Society (AGS) Beers Criteria recommends avoiding diphenhydramine in adults 65 and older because of its strong anticholinergic properties, high risk of confusion, and association with falls [9]. Adding diphenhydramine to a regimen that already includes other anticholinergic medications (oxybutynin, tricyclic antidepressants, certain antipsychotics) raises cumulative risk. Rosuvastatin itself has zero anticholinergic activity, so the statin is not a contributing factor here. The concern is entirely about diphenhydramine's own risk profile in this age group.

What DDI Databases and Clinical References Say

Major drug interaction databases handle this pair consistently. Lexicomp does not generate an interaction alert for rosuvastatin plus diphenhydramine [7]. Micromedex assigns no severity rating to the combination. The FDA label for Crestor lists specific interacting drugs by name: cyclosporine, atazanavir/ritonavir, simeprevir, gemfibrozil, fenofibrate, niacin, lopinavir/ritonavir, coumarin anticoagulants, and aluminum/magnesium hydroxide antacids (timing-dependent) [3]. Diphenhydramine is absent from that list.

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for statins focus on SLCO1B1 genotype (the gene encoding OATP1B1) and ABCG2 genotype (encoding BCRP) as pharmacogenomic determinants of statin exposure [10]. A patient who carries a reduced-function SLCO1B1 variant (such as *5/*5) has inherently higher rosuvastatin levels and might theoretically be more sensitive to any added metabolic or transport inhibition. Even in this subgroup, diphenhydramine would not meaningfully alter rosuvastatin pharmacokinetics because it does not inhibit the relevant transport proteins.

Monitoring and Patient Counseling Guidance

No dose adjustment is necessary for either rosuvastatin or diphenhydramine when the two drugs are taken together. Routine lab monitoring for the combination beyond standard statin monitoring (baseline lipid panel, hepatic transaminase check if clinically indicated, creatine kinase only if symptoms arise) is not required [3].

Practical counseling points for patients taking this combination:

For patients of any age: Rosuvastatin can be taken at its prescribed dose and timing without modification. If diphenhydramine is being used for allergies, a second-generation antihistamine (cetirizine, loratadine, fexofenadine) is generally preferred because these agents cause less sedation and have no additional interaction risk with rosuvastatin [11].

For adults aged 65 and older: The AGS Beers Criteria recommend against routine use of diphenhydramine regardless of statin status [9]. If a short course is medically necessary (acute allergic reaction, pre-procedure prophylaxis), the lowest effective dose for the shortest duration is appropriate. Monitor for confusion, urinary retention, and fall risk during the treatment window.

For patients on multiple CYP2D6-metabolized drugs: Although rosuvastatin is unaffected, diphenhydramine's CYP2D6 inhibition can raise levels of other medications in the regimen. Patients taking codeine (a CYP2D6 prodrug) may experience reduced analgesic efficacy; patients taking metoprolol or other CYP2D6-substrate beta-blockers may see increased beta-blocker exposure [2]. The interaction to watch for involves diphenhydramine's effect on those other drugs, not on the statin.

When the Statin Interaction Risk Is Real

To put the rosuvastatin-diphenhydramine non-interaction in context, here are the combinations with rosuvastatin that do require clinical action.

Cyclosporine co-administration increases rosuvastatin AUC by 7.1-fold. The FDA mandates a maximum rosuvastatin dose of 5 mg daily [3]. Gemfibrozil raises rosuvastatin AUC by approximately 1.9-fold, and the dose is capped at 10 mg daily [3]. The JUPITER trial (N=17,802), which established rosuvastatin 20 mg as effective for primary ASCVD prevention in patients with elevated hsCRP, excluded patients on these strong interacting drugs from enrollment [12].

Atazanavir/ritonavir increases rosuvastatin AUC by 3.1-fold and Cmax by 7-fold, with a recommended maximum rosuvastatin dose of 10 mg [3]. These interactions are driven by OATP1B1/1B3 inhibition and, in some cases, BCRP inhibition. They represent the molecular vulnerability of rosuvastatin's disposition pathway.

Diphenhydramine targets none of these mechanisms. The interaction gap between diphenhydramine and the drugs listed above is not a matter of degree. It is a matter of entirely different molecular targets.

Special Populations and Extended Considerations

Renal impairment: Rosuvastatin exposure increases in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), and the FDA label recommends starting at 5 mg with a maximum of 10 mg in this group [3]. Diphenhydramine clearance also decreases with renal impairment, potentially increasing sedation and anticholinergic effects [6]. While these changes are independent of each other (neither drug affects the other's renal handling), the net result in a renally impaired patient is higher circulating levels of both drugs. Clinical vigilance for diphenhydramine-related adverse effects is warranted, though this is not an interaction per se.

Hepatic impairment: Rosuvastatin is contraindicated in active liver disease or unexplained persistent transaminase elevations [3]. Diphenhydramine undergoes significant first-pass hepatic metabolism, and patients with cirrhosis may have prolonged effects [6]. Again, these are parallel pharmacokinetic changes, not a drug-drug interaction.

Pregnancy: Rosuvastatin is contraindicated in pregnancy [3]. This is unrelated to diphenhydramine but worth noting because some patients may use diphenhydramine for nausea during early pregnancy without realizing their statin should have been discontinued.

CYP2D6 poor metabolizers: Approximately 5-10% of the Caucasian population and 1-2% of Asian populations are CYP2D6 poor metabolizers [2]. These individuals already have reduced diphenhydramine clearance, and adding a CYP2D6 inhibitor on top has no further effect. Rosuvastatin exposure is unaffected by CYP2D6 status because the statin does not use this enzyme.

The Bottom Line on Concurrent Use

The rosuvastatin-diphenhydramine combination has no pharmacokinetic interaction supported by mechanistic data, in vitro screening, or clinical DDI databases. Rosuvastatin's reliance on OATP1B1/1B3 uptake and BCRP efflux, combined with its minimal CYP-mediated metabolism, places it outside diphenhydramine's sphere of enzymatic influence. Patients filling both prescriptions (or picking up OTC diphenhydramine while on Crestor) can take them without dose modification. The one clinical conversation worth having is whether diphenhydramine is the best antihistamine choice at all, particularly for patients over 65, where second-generation alternatives offer comparable efficacy with a cleaner safety profile [9][11].